RxDoctor Payments Data

James Gallagher Iii, MD

Vascular Surgery · Meriden, CTNPI 1053592964

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,583 of the $3,488 with a category attached, or 74.0%. 9 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 46.5% of the total. Reporting peaked in 2019 at $1,856 and has fallen 94.2% since, to $108 in 2025. That places this record below the midpoint for vascular surgery clinicians in CT, where the typical reported total is $7,252.

$3,488in general payments, 2019–2025

Across 28 payments — averaging $124.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$2K
  • Angiodynamics, Inc.$1K
  • Silk Road Medical, Inc.$158
  • Bolton Medical Inc$142
  • Endologix LLC$120
  • Cook Medical LLC$108
  • plus $175 from 3 others

What the payments were for

  • Travel & lodging$90626%
  • Food & beverage$2,58374%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,488 in reported general payments places this provider in the 35th percentile of 82 vascular surgery providers in Connecticut.

See all vascular surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$195,274
Medicare patients
987
Services billed
1,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levemir FlexpenInsulin Detemir22$1,709
ClopidogrelClopidogrel Bisulfate71$881
Atorvastatin Calcium39$639
Cilostazol29$479
Finasteride13$351

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Meriden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →